estradiol hemihydrate: clinical use

Prescribing considerations

• Confirm the indication, symptom burden and relevant personal and family history before starting systemic HRT.
• If the uterus is present, ensure adequate endometrial protection accompanies systemic estradiol unless a specialist rationale applies.
• Investigate unexplained genital bleeding before treatment and reassess new, persistent or heavier bleeding during treatment.
• Consider route-specific risks: transdermal estradiol avoids hepatic first-pass metabolism and has a lower blood-clot risk than oral HRT.
• Counsel about accidental transfer of estradiol gel, particularly to children.

Contraindications and cautions

• Known, previous or suspected breast cancer or another oestrogen-dependent malignancy
• Unexplained genital bleeding or untreated endometrial hyperplasia
• Previous or current venous thromboembolism, known thrombophilia, or active or recent arterial thromboembolic disease
• Acute liver disease, or previous liver disease while liver function remains abnormal
• Hypersensitivity to the active ingredient or excipients
• Porphyria

Monitoring

• Review benefits, risks, symptom control and ongoing need periodically.
• Ensure breast and cervical screening is maintained where appropriate and assess reported breast changes.
• Review bleeding patterns and investigate unexplained, persistent, heavy or newly changed bleeding.
• Reassess promptly if jaundice, significant blood-pressure increase, new migraine-type headache or thromboembolic symptoms develop.
• For relevant interactions, monitor clinical effect, bleeding pattern, seizure control or interacting-drug concentrations as appropriate.

Clinical pharmacology

Estradiol hemihydrate supplies 17β-estradiol, which activates oestrogen receptors. Oral estradiol undergoes gastrointestinal absorption and hepatic first-pass metabolism; transdermal administration bypasses first-pass metabolism. Vaginal Vagirux produces mainly local effects, with average systemic concentrations remaining within the postmenopausal range in pharmacokinetic studies.

Formulation and product differences

• Oral tablets provide systemic exposure and have more hepatic first-pass effects than transdermal products.
• Patches provide continuous transdermal delivery but differ by brand in design, approved indication, application site and replacement instructions.
• Sandrena is an alcohol-based transdermal gel that must dry before dressing and can transfer through skin contact.
• Vagirux is a local vaginal tablet with very low systemic absorption. It treats vaginal atrophy rather than general symptoms such as hot flushes.
• Only some selected systemic products are licensed for osteoporosis prevention; check the individual product information.

Gel

Route: Cutaneous

Strengths: 0.5 mg, 1.0 mg

Tablet

Route: Oral

Strengths: 1 mg, 2 mg

Transdermal patch

Transdermal